## fill, Carol

From:

Chris <chrisfitz65@hotmail.com>

Sent:

Tuesday, March 03, 2015 2:59 PM

To:

Hill, Carol

Subject:

TheraSphere training record for Brian Christenson St. Vincent healthcare Billings Mt

**Attachments:** 

Dr. Christenson Training record final 2-2015.docx

Good Afternoon Carol, please accept the attached document confirming Brian Christenson has completed his required 3 cases under a proctor for TheraSpheres at St Vincent Healthcare. I sent notification of his first case in January and the second two cases were completed on 02/06/15.

Thank you

Chris Fitz, RSO St Vincent Healthcare billings MT.

25-01553-01

☐ Immediate Release Normal Release

NON-PUBLIC

☐ A.3 Sensitive-Security Related

☐ A.7 Sensitive Internal

Other:

Date: 3-30-2015

BTG International Canada Inc. Roy Errington Building 3rd Floor 447 March Road

Ottawa, Ontario Canada K2K 1X8

+1 613 801 1880 Tel: Fax: +1 613 701 4086

Email: info@btgplc.com



**PUBLIC** ☐ Immediate Release Normal Release

NON-PUBLIC

☐ A.3 Sensitive-Security Related

■ A.7 Sensitive Internal Other:

To:

Chris Fitz, RSO; Brian Christenson MD

From:

Mark Moe

Date:

2/6/15

Subject:

TheraSphere® In-vitro/ In-vivo Administration Training for Authorized Users.

I am pleased to confirm that Brian Christenson MD has successfully completed the U.S.NRC required Authorized User (AU) manufacturer provided training for TheraSphere® Y-90 Glass Microspheres System through the path outlined below:

Vendor radiation safety lecture and three in-vitro set assemblies were conducted on 12/18/14. The user has successfully completed training in the operation of the delivery system, safety procedures, and clinical use for TheraSphere provided by BTG, including three supervised hands-on in-vitro simulated cases.

Brian Christenson MD completed training with three in-vivo cases on the dates of 12/19/14 and two cases on 2/6/15. Mark Moe, Interventional Oncology Proctor for BTG supervised/trained users at the above cases.

- a) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;
- b) Performing quality control procedures on instruments used to determine the activity of Y-90 microspheres and performing checks for proper operation of survey meters;
- c) Evaluation of each patient or human research subject for the dose/activity of Y-90 microspheres to be administered to each treatment site;
- d) Calculating and measuring the activity and safely preparing the Y-90 microspheres to be delivered to the patient or human research subject;
- e) Using administrative controls to prevent a medical event involving the use of byproduct material;
- f) Using procedures to control and to contain spilled byproduct material, including Y-90 microspheres, safely and using proper decontamination procedures; and
- g) Follow up and review of each patient's or human research subject's case history for Y-90 microspheres; and the user has successfully completed training in the operation of the delivery system, safety procedures, and clinical use for TheraSphere provided by BTG, including three supervised hands-on invitro cases.

This completes the BTG training for TheraSphere®. I look forward to working with you and your staff to develop a successful Y-90 TheraSphere® program at your hospital.

Sincerely,

Mark Moe

Interventional Oncology Proctor, TheraSphere BTG Inc.

M 586373

NRC	FORM	532

(1-2012)



DATE

U. S. NUCLEAR REGULATORY COMMISSION

TATE OF THE STATE	03/27/2015			
NAME AND ADDRESS OF APPLICANT AND/OR LICE	NSEE	LICENSE NUMBER		
Christopher K. Fitz		25-07553-01		
Radiation Safety Officer		MAIL CONTROL NUMBER		
St. Vincent Healthcare P.O. Box 35200		586373		
Billings, Montana 59107-5200		LICENSING AND/OR TECHNICAL REVIEWER		
8.,		СН		
This is to acknowledge the receipt	of your:			
✓ LETTER and/or	APPLICATION	DATED: 03/03/2015		
The initial processing, which included an administrative review, has been performed.				
✓ AMENDMENT    TERMINATION    NEW LICENSE    RENEWAL				
There were no administrative omissions identified during our initial review.				
This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.				
Your application for a new NRC license did not include your taxpayer identification number. Please fill out NRC Form 531, located at the following link:				
http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf				
Send the completed NRC Form 531, by facsimile, to the following number: (301) 415-5387				
		Fee and Accounts Receivable Branch, in ontacted separately if there is a fee issue		
calling to inquire about this action been forwarded to a technical rev normally completed within 180 da	n, please refer to this c viewer. Please note th ays for a renewal appli or require additional i	cation (90 days for all other requests), nformation. If you have any questions		
5-1				

Region IV U. S. Nuclear Regulatory Commission DNMS/NMSB - B 1600 E. Lamar Boulevard Arlington, TX 76011-4511 (817) 200-1103 or (817) 200-1140

NRC FORM 532 (1-2012)

## [FOR ARPB USE] BETWEEN: INFORMATION FROM WBL Accounts Receivable/Payable and Program Code: 02230 Status Code: Pending Amendment Regional Licensing Branches Fee Category: 7C Exp. Date: 04/30/2015 Fee Comments: Decom Fin Assur Regd: License Fee Worksheet - License Fee Transmittal A. REGION 1. APPLICATION ATTACHED ST. VINCENT HEALTHCARE Applicant/Licensee: Received Date: 03/03/2015 3002396 Docket Number: 586373 Mail Control Number: 25-07553-01 License Number: Notifications Action Type: 2. FEE ATTACHED Amount: Check No .: 3. COMMENTS Signed: Date: B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / / 1. Fee Category and Amount: 2. Correct Fee Paid. Application may be processed for: Amendment: Renewal: License: 3. OTHER \_

Signed:

Date: